Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1969 1
1970 2
1982 1
1984 1
1985 1
1986 2
1987 3
1988 7
1989 17
1990 8
1991 18
1992 8
1993 9
1994 19
1995 14
1996 26
1997 18
1998 23
1999 20
2000 29
2001 19
2002 34
2003 37
2004 34
2005 34
2006 45
2007 67
2008 53
2009 86
2010 77
2011 125
2012 95
2013 84
2014 95
2015 94
2016 89
2017 119
2018 86
2019 119
2020 111
2021 119
2022 97
2023 119
2024 26

Text availability

Article attribute

Article type

Publication date

Search Results

1,917 results

Results by year

Filters applied: . Clear all
Page 1
HIV infection: epidemiology, pathogenesis, treatment, and prevention.
Maartens G, Celum C, Lewin SR. Maartens G, et al. Lancet. 2014 Jul 19;384(9939):258-71. doi: 10.1016/S0140-6736(14)60164-1. Epub 2014 Jun 5. Lancet. 2014. PMID: 24907868 Review.
HIV prevalence is increasing worldwide because people on antiretroviral therapy are living longer, although new infections decreased from 3.3 million in 2002, to 2.3 million in 2012. ...The role of immune activation in the pathogenesis of non-AIDS clinical events (major ca …
HIV prevalence is increasing worldwide because people on antiretroviral therapy are living longer, although new infections decreased …
Treatment of inflammatory complications in common variable immunodeficiency (CVID): current concepts and future perspectives.
Fevang B. Fevang B. Expert Rev Clin Immunol. 2023 Jun;19(6):627-638. doi: 10.1080/1744666X.2023.2198208. Epub 2023 Apr 6. Expert Rev Clin Immunol. 2023. PMID: 36996348 Review.
INTRODUCTION: Patients with common variable immunodeficiency (CVID) have a high frequency of inflammatory complications like autoimmune cytopenias, interstitial lung disease and enteropathy. ...Treating the underlying immune dysregulation and immune exhaustion in CVID is a …
INTRODUCTION: Patients with common variable immunodeficiency (CVID) have a high frequency of inflammatory complications like autoimmu …
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY GUIDELINES FOR MANAGEMENT OF DYSLIPIDEMIA AND PREVENTION OF CARDIOVASCULAR DISEASE.
Jellinger PS, Handelsman Y, Rosenblit PD, Bloomgarden ZT, Fonseca VA, Garber AJ, Grunberger G, Guerin CK, Bell DSH, Mechanick JI, Pessah-Pollack R, Wyne K, Smith D, Brinton EA, Fazio S, Davidson M. Jellinger PS, et al. Endocr Pract. 2017 Apr;23(Suppl 2):1-87. doi: 10.4158/EP171764.APPGL. Endocr Pract. 2017. PMID: 28437620
These detailed, evidence-based recommendations allow for nuance-based clinical decision-making that addresses multiple aspects of real-world medical care. The evidence base presented in the subsequent Appendix provides relevant supporting information for Executive Summary …
These detailed, evidence-based recommendations allow for nuance-based clinical decision-making that addresses multiple aspects of real-world …
Characterization of the clinical and immunologic phenotype and management of 157 individuals with 56 distinct heterozygous NFKB1 mutations.
Lorenzini T, Fliegauf M, Klammer N, Frede N, Proietti M, Bulashevska A, Camacho-Ordonez N, Varjosalo M, Kinnunen M, de Vries E, van der Meer JWM, Ameratunga R, Roifman CM, Schejter YD, Kobbe R, Hautala T, Atschekzei F, Schmidt RE, Schröder C, Stepensky P, Shadur B, Pedroza LA, van der Flier M, Martínez-Gallo M, Gonzalez-Granado LI, Allende LM, Shcherbina A, Kuzmenko N, Zakharova V, Neves JF, Svec P, Fischer U, Ip W, Bartsch O, Barış S, Klein C, Geha R, Chou J, Alosaimi M, Weintraub L, Boztug K, Hirschmugl T, Dos Santos Vilela MM, Holzinger D, Seidl M, Lougaris V, Plebani A, Alsina L, Piquer-Gibert M, Deyà-Martínez A, Slade CA, Aghamohammadi A, Abolhassani H, Hammarström L, Kuismin O, Helminen M, Allen HL, Thaventhiran JE, Freeman AF, Cook M, Bakhtiar S, Christiansen M, Cunningham-Rundles C, Patel NC, Rae W, Niehues T, Brauer N, Syrjänen J, Seppänen MRJ, Burns SO, Tuijnenburg P, Kuijpers TW; NIHR BioResource; Warnatz K, Grimbacher B; NIHR BioResource. Lorenzini T, et al. J Allergy Clin Immunol. 2020 Oct;146(4):901-911. doi: 10.1016/j.jaci.2019.11.051. Epub 2020 Apr 9. J Allergy Clin Immunol. 2020. PMID: 32278790 Free PMC article.
The phenotype included hypogammaglobulinemia (88.9%), reduced switched memory B cells (60.3%), and respiratory (83%) and gastrointestinal (28.6%) infections, thus characterizing the disorder as primary immunodeficiency. However, the high frequency of autoimmunity (57.4%), …
The phenotype included hypogammaglobulinemia (88.9%), reduced switched memory B cells (60.3%), and respiratory (83%) and gastrointestinal (2 …
Expanded Multivariable Models to Assist Patient Selection for Long-Acting Cabotegravir + Rilpivirine Treatment: Clinical Utility of a Combination of Patient, Drug Concentration, and Viral Factors Associated With Virologic Failure.
Orkin C, Schapiro JM, Perno CF, Kuritzkes DR, Patel P, DeMoor R, Dorey D, Wang Y, Han K, Van Eygen V, Crauwels H, Ford SL, Latham CL, St Clair M, Polli JW, Vanveggel S, Vandermeulen K, D'Amico R, Garges HP, Zolopa A, Spreen WR, van Wyk J, Cutrell AG. Orkin C, et al. Clin Infect Dis. 2023 Nov 17;77(10):1423-1431. doi: 10.1093/cid/ciad370. Clin Infect Dis. 2023. PMID: 37340869 Free PMC article.
Retained factors were evaluated to understand their contribution to CVF (alone or in combination). RESULTS: Overall, 1.4% (n = 23/1651) of participants had CVF through 152 weeks. The presence of RPV resistance-associated mutations, human immunodeficiency virus-1 sub …
Retained factors were evaluated to understand their contribution to CVF (alone or in combination). RESULTS: Overall, 1.4% (n = 23/165 …
Major revision version 11.0 of the European AIDS Clinical Society Guidelines 2021.
Ryom L, De Miguel R, Cotter AG, Podlekareva D, Beguelin C, Waalewijn H, Arribas JR, Mallon PWG, Marzolini C, Kirk O, Bamford A, Rauch A, Molina JM, Kowalska JD, Guaraldi G, Winston A, Boesecke C, Cinque P, Welch S, Collins S, Behrens GMN; EACS Governing Board. Ryom L, et al. HIV Med. 2022 Sep;23(8):849-858. doi: 10.1111/hiv.13268. Epub 2022 Mar 25. HIV Med. 2022. PMID: 35338549 Free PMC article.
BACKGROUND: The European AIDS Clinical Society (EACS) Guidelines were revised in 2021 for the 17th time with updates on all aspects of HIV care. KEY POINTS OF THE GUIDELINES UPDATE: Version 11.0 of the Guidelines recommend six first-line treatment options for antiretrovira …
BACKGROUND: The European AIDS Clinical Society (EACS) Guidelines were revised in 2021 for the 17th time with updates on all aspects of HIV …
Disparities by province, age, and sex in site-specific cancer burden attributable to 23 potentially modifiable risk factors in China: a comparative risk assessment.
Chen W, Xia C, Zheng R, Zhou M, Lin C, Zeng H, Zhang S, Wang L, Yang Z, Sun K, Li H, Brown MD, Islami F, Bray F, Jemal A, He J. Chen W, et al. Lancet Glob Health. 2019 Feb;7(2):e257-e269. doi: 10.1016/S2214-109X(18)30488-1. Lancet Glob Health. 2019. PMID: 30683243 Free article.
In this report, we estimate the site-specific population-attributable fractions (PAFs) for 23 potentially modifiable risk factors across all provinces in China. ...FINDINGS: About 1 036 004 cancer deaths (45.2% of all cancer deaths [95% CI 44.0-46.4]) in China in 2014 in a …
In this report, we estimate the site-specific population-attributable fractions (PAFs) for 23 potentially modifiable risk factors acr …
Recommendations for Management of Secondary Antibody Deficiency in Multiple Myeloma.
Giralt S, Jolles S, Kerre T, Lazarus HM, Mustafa SS, Papanicolaou GA, Ria R, Vinh DC, Wingard JR. Giralt S, et al. Clin Lymphoma Myeloma Leuk. 2023 Oct;23(10):719-732. doi: 10.1016/j.clml.2023.05.008. Epub 2023 May 23. Clin Lymphoma Myeloma Leuk. 2023. PMID: 37353432 Free article. Review.
Secondary antibody deficiency (SAD) is a subtype of secondary immunodeficiency characterized by low serum antibody concentrations (hypogammaglobulinemia) or poor antibody function. ...Patients with SAD are more susceptible to infections and infection-related morbidi …
Secondary antibody deficiency (SAD) is a subtype of secondary immunodeficiency characterized by low serum antibody concentrati …
Diagnosis and management of Specific Antibody Deficiency.
Perez EE, Ballow M. Perez EE, et al. Immunol Allergy Clin North Am. 2020 Aug;40(3):499-510. doi: 10.1016/j.iac.2020.03.005. Epub 2020 Jun 9. Immunol Allergy Clin North Am. 2020. PMID: 32654695 Review.
Specific antibody deficiency is a primary immunodeficiency disease recognized by the International Union of Immunology Societies and defined by recurrent respiratory infections with normal immunoglobulins, but diminished antibody responses to polysaccharide antigens …
Specific antibody deficiency is a primary immunodeficiency disease recognized by the International Union of Immunology Societi …
Exploring and Prioritization of Mobile-Based Self-Management Strategies for HIV Care.
Mehraeen E, Safdari R, SeyedAlinaghi S, Mohammadzadeh N. Mehraeen E, et al. Infect Disord Drug Targets. 2019;19(3):288-296. doi: 10.2174/1871526518666181022113900. Infect Disord Drug Targets. 2019. PMID: 30345930 Review.
This study aims at (i) identifying in the literature mobile-based self-management strategies for HIV care and (ii) prioritizing those from the point of view of infectious diseases specialists. ...In the second phase, identified mobile-based self-management strategies were …
This study aims at (i) identifying in the literature mobile-based self-management strategies for HIV care and (ii) prioritizing those …
1,917 results